Health Technology · Pharmaceuticals: Major · NSE: DIVISLAB · data 2026-10-09
Divi's Laboratories Limited
Health check: Average (6.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹9,340
Market cap
₹2,49,248 cr
P/E
84.8
P/B
—
ROE
16.2%
ROCE
18.0%
Debt / equity
0
Dividend yield
0.32%
1-year return
51.9%
52-week high
₹9,740
52-week low
₹5,647.5
Operating margin
31.0%
Growth
| Revenue (last 12 months) | ₹11,230 cr |
| Net profit (last 12 months) | ₹2,925 cr |
| Sales growth, 3 years (yearly) | 10.8% |
| Profit growth, 3 years (yearly) | 12.1% |
Similar companies
Sun Pharmaceutical Industries Limited (SUNPHARMA) · Torrent Pharmaceuticals Ltd (TORNTPHARM) · Zydus Lifesciences Limited (ZYDUSLIFE) · Laurus Labs Ltd. (LAURUSLABS) · Mankind Pharma Ltd. (MANKIND)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open DIVISLAB in NSE Scanner →